We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies.
- Authors
Lidsky, Michael E.; Wang, Zechen; Lu, Min; Liu, Annie; Hsu, S. David; McCall, Shannon J.; Sheng, Zhecheng; Granek, Joshua A.; Owzar, Kouros; Anderson, Karen S.; Wood, Kris C.
- Abstract
Intrahepatic cholangiocarcinoma (ICC) remains a deadly malignancy lacking systemic therapies for advanced disease. Recent advancements include selective FGFR1–3 inhibitors for the 15% of ICC patients harboring fusions, although survival is limited by poor response and resistance. Herein we report generation of a patient-derived FGFR2 fusion-positive ICC model system consisting of a cell line, organoid, and xenograft, which have undergone complete histologic, genomic, and phenotypic characterization, including testing standard-of-care systemic therapies. Using these FGFR2 fusion-positive ICC models, we conducted an unbiased high-throughput small molecule screen to prioritize combination strategies with FGFR inhibition, from which HDAC inhibition together with pemigatinib was validated in vitro and in vivo as a synergistic therapy for ICC. Additionally, we demonstrate broad utility of the FGFR/HDAC combination for other FGFR fusion-positive solid tumors. These data are directly translatable and justify early phase trials to establish dosing, safety, and therapeutic efficacy of this synergistic combination.
- Subjects
CHOLANGIOCARCINOMA; SMALL molecules; CELL lines; TREATMENT effectiveness
- Publication
NPJ Precision Oncology, 2022, Vol 6, Issue 1, p1
- ISSN
2397-768X
- Publication type
Article
- DOI
10.1038/s41698-022-00320-5